SG11201901925RA - Methods of treating acute kidney injury - Google Patents
Methods of treating acute kidney injuryInfo
- Publication number
- SG11201901925RA SG11201901925RA SG11201901925RA SG11201901925RA SG11201901925RA SG 11201901925R A SG11201901925R A SG 11201901925RA SG 11201901925R A SG11201901925R A SG 11201901925RA SG 11201901925R A SG11201901925R A SG 11201901925RA SG 11201901925R A SG11201901925R A SG 11201901925RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- english
- pct
- applicant
- Prior art date
Links
- 208000009304 Acute Kidney Injury Diseases 0.000 title abstract 3
- 208000033626 Renal failure acute Diseases 0.000 title abstract 3
- 201000011040 acute kidney failure Diseases 0.000 title abstract 3
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404390P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055400 WO2018067857A1 (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901925RA true SG11201901925RA (en) | 2019-04-29 |
Family
ID=60153507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901925RA SG11201901925RA (en) | 2016-10-05 | 2017-10-05 | Methods of treating acute kidney injury |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20210283116A1 (ko) |
| EP (1) | EP3522880B1 (ko) |
| JP (1) | JP7065839B2 (ko) |
| KR (1) | KR20190062502A (ko) |
| CN (1) | CN109789117B (ko) |
| AU (1) | AU2017340760B2 (ko) |
| BR (1) | BR112019005539A2 (ko) |
| CA (1) | CA3036723A1 (ko) |
| CO (1) | CO2019004561A2 (ko) |
| CY (1) | CY1124759T1 (ko) |
| DK (1) | DK3522880T3 (ko) |
| ES (1) | ES2859487T3 (ko) |
| HR (1) | HRP20210294T1 (ko) |
| HU (1) | HUE053557T2 (ko) |
| IL (1) | IL265749A (ko) |
| JO (1) | JOP20190056B1 (ko) |
| LT (1) | LT3522880T (ko) |
| MA (1) | MA46459B1 (ko) |
| MD (1) | MD3522880T2 (ko) |
| MX (1) | MX2019003949A (ko) |
| MY (1) | MY192385A (ko) |
| PH (1) | PH12019500725A1 (ko) |
| PL (1) | PL3522880T3 (ko) |
| PT (1) | PT3522880T (ko) |
| RS (1) | RS61573B1 (ko) |
| RU (1) | RU2753607C2 (ko) |
| SG (1) | SG11201901925RA (ko) |
| SI (1) | SI3522880T1 (ko) |
| TW (1) | TWI778982B (ko) |
| UA (1) | UA124019C2 (ko) |
| WO (1) | WO2018067857A1 (ko) |
| ZA (1) | ZA201901743B (ko) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113024467B (zh) | 2015-10-07 | 2024-08-06 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| MX2018012538A (es) * | 2016-04-13 | 2019-02-25 | Mitobridge Inc | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos. |
| AU2017340763B2 (en) | 2016-10-05 | 2021-10-07 | Mitobridge, Inc. | Crystalline and salt forms of PPAR agonist compounds |
| KR20220042150A (ko) | 2019-07-19 | 2022-04-04 | 비포르 (인터내셔날) 아게 | 신장 손상의 예방 및 치료에의 용도를 위한 페로포틴 억제제 |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN115813901B (zh) * | 2022-10-20 | 2024-10-22 | 南京市儿童医院 | 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1670744T1 (sl) * | 2003-09-19 | 2010-11-30 | Janssen Pharmaceutica Nv | fenoksialkil tio fenoksiocetne kisline in analogi |
| KR20070036076A (ko) * | 2004-05-25 | 2007-04-02 | 메타볼렉스, 인코포레이티드 | Ｐｐａｒ의 조절제로서의 치환된 트리아졸 및 이의제조방법 |
| RU2320341C1 (ru) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Средство для лечения острой обструкции верхних мочевыводящих путей |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| CA2740874C (en) * | 2008-10-17 | 2018-02-27 | Metabolex, Inc. | Use of ppar.gamma.agonists to reduce small dense ldl particles |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| CN105324395A (zh) * | 2013-03-08 | 2016-02-10 | 艾伯维公司 | 治疗急性肾损伤的方法 |
| WO2014165827A1 (en) * | 2013-04-05 | 2014-10-09 | Salk Institute For Biological Studies | Ppar agonists |
| EP2862574A1 (en) * | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
| CN105917229B (zh) * | 2013-12-03 | 2019-04-26 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| WO2016057656A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
| CN113024467B (zh) * | 2015-10-07 | 2024-08-06 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
-
2017
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/ar active
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/hu unknown
- 2017-10-05 MA MA46459A patent/MA46459B1/fr unknown
- 2017-10-05 TW TW106134387A patent/TWI778982B/zh active
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/ru active
- 2017-10-05 MX MX2019003949A patent/MX2019003949A/es unknown
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/en active Active
- 2017-10-05 PT PT177877735T patent/PT3522880T/pt unknown
- 2017-10-05 PL PL17787773T patent/PL3522880T3/pl unknown
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/ro unknown
- 2017-10-05 RS RS20210203A patent/RS61573B1/sr unknown
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/zh active Active
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en active Active
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/ko not_active Application Discontinuation
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 SI SI201730653T patent/SI3522880T1/sl unknown
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/da active
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/ja active Active
- 2017-10-05 BR BR112019005539A patent/BR112019005539A2/pt not_active Application Discontinuation
- 2017-10-05 CA CA3036723A patent/CA3036723A1/en active Pending
- 2017-10-05 UA UAA201904011A patent/UA124019C2/uk unknown
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/lt unknown
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/en active Application Filing
- 2017-10-05 ES ES17787773T patent/ES2859487T3/es active Active
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/es unknown
-
2021
- 2021-02-22 HR HRP20210294TT patent/HRP20210294T1/hr unknown
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901925RA (en) | Methods of treating acute kidney injury | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201811074RA (en) | Nant cancer vaccine | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201909107YA (en) | Stenosis treatment | |
| SG11201808829VA (en) | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |